Background: In Austria phase II cardiology post-acute care is generally carried out as an inpatient. Further follow-up (Phase III) takes place as an outpatient, in accordance with the standards of the Austrian Working Group on Outpatient Cardiac Rehabilitation (in cooperation with the Austrian Society of Cardiology). Exercise training is carried out over a time period of six to twelve months in order to extend maximal physical capacity, to gain information about cardiac risk factors and to change patient behaviour. The aim is to improve lifestyle habits with regard to physical activity and nutrition, in order to limit progression of the disease. Purpose: This work presents the medical outcomes of outpatient phase III rehabilitation, while taking into account the results of the preceding inpatient phase II. Method: During the course of phase III, data was collected from 140 patients with stable cardiovascular disease. At the beginning and end of phase III the body mass index (BMI), lipids and blood glucose were determined, and the blood pressure was measured. In order to assess physical fitness, a staged bicycle ergometer test was carried out to the point where the patient reached his or her maximal exercise capacity. Information about symptoms and quality of life (MacNew) was obtained using surveys. The outcome parameters combined in terms of content and factor analysis to create a "Health Index" (H-Index). This can be interpreted as an expression of the current state of health or of the constitution. Results: The average age of the subjects was 62.4 +/-10.3 years, with women accounting for 26.4% of subjects. The phase III patients attended for phase III follow-up on average at 6.3 +/-4.3 weeks after the inpatient phase II. This lasted for 29.3 +/-9.2 weeks with a total of 48.1 +/-13.8 units of outpatient therapy carried out. The H-Index of 36% of patients improved during the phase III intervention. Considering phase II results it was possible to stabilize the H-Index at a good level in 56% of patients. Only 9% showed a worsening of their state of health at the end of phase III (p<.01**). Physical fitness improved by 19.1 +/-20.5 Watts (from 111.9 to 131.0 Watts), as did quality of life (p=.000***). There was no significant change in blood pressure (p=.10) or in metabolic parameters (LDL, triglycerides, blood glucose; p>35). Only body weight was shown to increase in approx. 44.3% of patients over the course of phase III (average weight increase: 1.6 +/-3.3 kg, i.e. BMI +0.6 +/-1.1, p=.000***). Conclusion: Quality of life and fitness in particular were significantly improved in the majority of the cardiology patients, or were stabilized at a good level, leading to a reduction in morbidity and mortality. The results support the significance of and evidence for outpatient phase III rehabilitation. This is reflected in the high rates of satisfaction (95%) with the outpatient version.
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Internet-based cognitive behavior therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized trial Abstracts S63 symptoms of depression and anxiety among adults with common mental health difficulties but have so far not been evaluated in MI patients with symptoms of depression and anxiety. Purpose: The purpose of this randomized trial was to evaluate the effectiveness of an iCBT treatment to reduce self-reported symptoms of depression and anxiety among patients with a recent MI. Methods: In total, 3928 patients were screened in routine clinical care settings at 25 Swedish hospitals for study eligibility. Of these, 239 (33% women, mean age 60 years) with a recent MI (6-10 weeks) and symptoms of depression and anxiety were randomly allocated to a therapistguided, tailored, 14 week iCBT treatment (n=117), or treatment as usual (n=122). The iCBT treatment consisted of 10 eligible modules, designed for an MI patient population. The primary outcome was the potential difference between groups in the total score of the Hospital Anxiety and Depression Scale (HADS) at follow-up 14 weeks post baseline. Treatment effect was evaluated according to the intention-to-treat principle, with multiple imputation performed to handle missing values. For the main analysis, a pooled treatment effect was estimated with a multiple linear model, controlling for age, sex, and baseline HADS.
Results: There was a reduction in HADS scores over time in the total study sample (mean Á = -5.1, P< 0.01). However, there was no difference in HADS score between the iCBT group and the control group at follow-up (b=-0.47 [95% confidence interval, -1.95 to 1.00], P=0.53). Treatment adherence was low, with 54% of the iCBT group not completing the introductory module, 39% completing the introductory module only, and 15% completing additional modules. Conclusions: iCBT treatment for an MI population, with patients recruited from routine cardiac care, did not result in lower levels of symptoms of depression or anxiety compared to treatment as usual. Reasons for low treatment adherence needs to be further explored. Aboriginal people in Australia have higher rates of hospitalised atrial fibrillation (AF) and stroke incidence than non-Aboriginal people. AF is a major cause of ischaemic stroke and cardiovascular (CV) mortality which is potentially preventable with oral anticoagulant therapy. There are limited data on stroke and CV mortality outcomes in Aboriginal vs non-Aboriginal patients with AF in Australia. Purpose: To compare the incidence and risk of stroke and CV mortality between Aboriginal and non-Aboriginal patients after hospitalisation for AF. Methods: People aged 20-84 years with a hospital discharge diagnosis of AF in 2000-2012 who survived 28-days were included in the cohort ('index admission'). Comorbidities, demographics and CHA?DS?-VASc score were identified from linked hospital data. Follow-up data were available for up to 10 years post index AF. The primary outcome was stroke (fatal or non-fatal); secondary outcome was CV mortality. Incidence rates were calculated for each outcome over the full follow-up period. Cox regression models with progressive adjustment were used to estimate the hazard ratio (HR) for outcomes in Aboriginal vs non-Aboriginal people. Results: There were 55,723 index AF cases (2.5% Aboriginal) with Aboriginals over-represented in 20-59 year olds (7.8%). Mean age in Aboriginal people was 56.5 years and 69.9 years in non-Aboriginal people. The mean CHA?DS?-VASc was higher in Aboriginal people, with 49% and 79% aged 20-59 and 60-84 years respectively having a CHA?DS?-VASc score !2, compared with 12% and 76% of non-Aboriginal people (p<0.001). The incidence rate of stroke in 20-59 year old Aboriginal people was 21/1000 person-years, and 6/1000 in non-Aboriginal people; corresponding rates in 60-84 year olds were 46/1000 and 28/1000. CV mortality rates were 51/1000 and 10/1000 in Aboriginal and non-Aboriginal people aged 20-59 years; corresponding rates in 60-84 year olds were 100/1000 and 64/1000. Crude HRs for risk of stroke and CV death in Aboriginal vs non-Aboriginal people were 3.22 (95%CI 2.54, 4.08) and 4.98 (4.26, 5.82) respectively in 20-59 year olds, and 1.62 (1.33, 1.97) and 1.56 (1.38, 1.78) in 60-84 year olds. The disparity by Aboriginal status remained significant in both age groups after full adjustment (stroke HR 1.87 and 1.79; CV mortality 1.70 and 1.56, p<0.001). Adjustment for AF as principal diagnosis at index admission, rural location and CHA?DS?-VASc score had the largest impact on attenuation of risk, particularly in the younger age group. Conclusion: Risk of stroke and CV mortality in Aboriginal people after AF hospitalisation is substantial and the disparity compared with non-Aboriginal people is greatest in younger Aboriginal people. These data highlight the importance of better educating Aboriginal people about AF, and the need for stringent application of evidence-based therapies, notably anticoagulant prophylaxis, in Aboriginal people with AF to reduce stroke and mortality risk. Aim: To determine the prevalence of HTN and to evaluate BP management in comparison to the EULAR recommendations in our Midwest RA cohort after devising departmental guidelines and continuous education based on the results of first audit cycle. Methods: 100 consecutive patients with definite RA were recruited in this multicenter quality improvement project involving 2 teaching hospitals (Croom hospital & University Hospital Limerick) between january-febuary2017. A proforma was completed for each patient based on medical notes & electronic data including BP record within the last 4 years and recent antihypertensive medications. HTN was defined as BP of !140/90 mmHg. Based on the EULAR guidelines, ACE inhibitors (ACE-I) & angiotensin II (AT-II) blockers are preferred agents when indicated due to favorable effect on inflammatory markers and the endothelial function in RA. Based upon the results of our first audit cycle, we encouraged the use of ACE-I and AT-II blockers in our RA cohort as the preferred antihypertensive agents when indicated at both departmental and community level. Results: 1) There was an overall improvement in BP monitoring by 4%, and 70% of the patients had up-to-date BP recordings. 2) There was 5% increment in hypertensive patient cohort (element of white coat HTN not excluded) and at least 45% of patients were suboptimally managed with mono or combination antihypertensive therapy in both cycles. Encouragingly ACE-I and AT-II blockers remained the main stay of treatment and constituted 50% of total drugs in the second audit compared to 54% in the first audit. 3) There were 6% reduction in the numbers of normotensive patients; 36% patients were adequately controlled with antihypertensive therapy in both audits. Interestingly the overall use of both ACE-I and AT-II blockers as primary antihypertensive was increased by 7% as compared to the first audit. Conclusion: Management of HTN in our RA cohort remained low and will require a re-audit. Several major barriers exist, including lack of time and staff. Rheumatologists need to be more actively involved in managing HTN in RA patients with possible referral to the relevant specialty if in doubt regarding the diagnosis and/or management.
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